JonesTrading analyst Soumit Roy maintained a Buy rating on Anavex Life Sciences (NASDAQ:AVXL) on Wednesday, setting a price target of $50, which is approximately 133.86% above the present share price of $21.38.
Roy expects Anavex Life Sciences to post earnings per share (EPS) of -$0.14 for the fourth quarter of 2021.
The current consensus among 3 TipRanks analysts is for a Strong Buy rating of shares in Anavex Life Sciences, with an average price target of $41.33.
The analysts price targets range from a high of $50 to a low of $35.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $0 and a net profit of -$11.36 million. The company's market cap is $1.62 billion.
According to TipRanks.com, JonesTrading analyst Soumit Roy is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 30.8% and a 44.98% success rate.
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.